Trial Profile
Anticoagulants for Living FoEtuses in women with recurrent miscarriage and inherited thrombophilia : ALIFE 2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Tinzaparin sodium (Primary)
- Indications Thrombophilia
- Focus Therapeutic Use
- Acronyms ALIFE 2
- 13 Dec 2022 Status changed to completed, according to Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Sep 2018 New trial record